Nanoptima Limited

NanOptima is redefining ocular drug delivery through NAAmatrix™ - a natural-amino-acid, bioresorbable long-acting matrix engineered for safety, scalability, and durability. Safe by design. Durable by nature. NAAmatrix™ extends proven retinal drugs such as Eylea® and Avastin® from 1–3-month dosing to beyond six months from a single standard intravitreal injection and integrates seamlessly into current workflows for frictionless clinical adoption, requiring no devices, surgery, synthetic implants /PLGA, curing, retraining, or new equipment. Tunable for duration, release rate, and dose, the platform is compatible across biologics, peptides, and small molecules, unlocking multi-billion-dollar lifecycle and pipeline opportunities in AMD, DME, DR, RVO, and GA. Built by former AstraZeneca leaders in protein science, injectable sustained release, and CMC, NanOptima is designed from day one for partner-ready translation and pharma collaboration.